23andMe competitors

Pichai Sundararajan (born June 10, 1972), better known as Sundar Pichai , is an Indian-American business executive. He is the chief executive officer (CEO) of Alphabet Inc. and its subsidiary Google.

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

John Melo has 30 years of combined experience as an entrepreneur and thought leader in developing and growing technology companies and as a senior executive in the Oil & Gas industry. As President and Chief Executive Officer, Mr. Melo has led Amyris through successful technology development, industrial start up, product development and commercialization and a series of funding rounds, including the initial public offering. Before joining Amyris in 2007, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum) most recently as President of U.S. fuels operations where he successfully led a business transformation and significantly improved the financial performance. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment; Senior Advisor for e-business strategy to Lord Browne, BP group chief executive; and Director of global brand development. In this last role, he helped develop the “Helios” re-branding effort. Before joining BP, Mr. Melo was with Ernst & Young. Mr. Melo currently serves on the board of directors of Renmatix Inc., serves on the board of directors of BayBio, serves on the Bio Industrial and Environmental section governing board, is a member of the Council for the Portuguese Diaspora and is a member of Young Presidents’ Organization (YPO). He was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. When not working on the mission of making sustainable chemistry mainstream or championing the eradication of malaria, John enjoys skiing, reading and time with his family on the island of Pico in the Azores, his childhood home.

Nick Leschly has served as our chief bluebird since September 2010. Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic Therapeutics.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Alison Mudditt became Director of University of California Press in January 2011. Throughout its 100-year history UC Press has consistently nurtured and brought breakthrough scholarly voices and study into critical and emerging academic disciplines. With an uncompromising commitment to a set of core values rooted in the University of California’s inclusive public mission and commitment to academic excellence, Alison has reshaped the Press’s strategy and structure to enable it to meet the needs of its diverse audiences in the digital age. She has helped the Press to work in new ways that respond to changes in publishing while continuing to shape progressive discourse and to tap the power of technology to deliver work the way it can best be accessed and used by our diverse audiences. Previously Alison was Executive Vice President at SAGE Publications, Inc., where she led the SAGE's publishing programs across books, journals and digital during a period of tremendous growth at SAGE, including the acquisition of CQ Press and new publishing partnerships with major scholarly organizations such as the Association for Psychological Science and the American Sociological Association. Alison has twenty-five years experience in academic publishing which began at Blackwell in Oxford, UK, where she rose to become Publisher for the Humanities Division. In 1997, Alison moved to Taylor & Francis Inc. in Philadelphia as Publishing Director of the Behavioral Sciences Division. She was responsible for the global growth and consolidation of this division, as well as the successful launch of Psychology Press in the USA. Alison joined SAGE in 2001 as Vice President and Editorial Director, and was appointed Executive Vice President in 2004. Alison is a regular speaker at industry meetings and is currently a member of the Scientific Publications Committee and the Open Science Committee of the American Heart Association. She has also served on the boards of Women in Publishing, the Society of Young Publishers, the Executive Council of the Professional and Scholarly Publishing Division of the American Association of Publishers, and was Co-chair of the Dean’s Leadership Council at California State University, Channel Islands.